Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

Cassidy, Jim; Clarke, Stephen; Díaz-Rubio, Eduardo; Scheithauer, Werner; Figer, Arie; Wong, Ralph; Koski, Sheryl; Lichinitser, Mikhail; Yang, Tsai-Shen; Rivera, Fernando; Couture, Felix; Sirzén, Florin; Saltz, Leonard

doi:10.1200/jco.2007.14.9898

Public

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

Shared by NobleBlocks on Apr 20, 2008 • 12:00 AM UTC

Authors:

Jim Cassidy

Stephen Clarke

Eduardo Díaz-Rubio

Abstract

PURPOSE: To evaluate whether capecitabine plus oxaliplatin (XELOX) is noninferior to fluorouracil. folinic acid, and oxaliplatin (FOLFOX-4) as first-line therapy in metastatic colorectal cancer (MCRC). PATIENTS AND METHODS: The initial design of this trial was a randomized, two-arm, noninferiority, ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!